BFRIW
Biofrontera Inc.
—
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
None
$0.01
(0.00%)
Price History
52-Week Range
Sign in to add BFRIW to a watchlist or set price alerts.
Fundamentals
| Market Cap | - |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-1.30 |
| Dividend Yield | - |
| Profit Margin | -13.79% |
| Revenue Growth | 32.90% |
| ROE | -988.35% |
| Debt/Equity | 125.99 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | - |
| Beta | 0.84 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $0.02 |
| 52-Week Low | $0.02 |
| 50-Day Avg | - |
| 200-Day Avg | - |
| Avg Volume | - |
| Volume | 212 |
Performance Analysis
NEUTRALBFRIW presents a mixed picture with both positive and negative indicators.
~
Trading at 50% of its 52-week range.
+
Strong revenue growth of 32.9% year-over-year.
-
Operating at a loss with -13.8% margin.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Sep 10, 2026 19:25 UTC
Back to Screener Export Report